Welcome to our dedicated page for Polypid news (Ticker: PYPD), a resource for investors and traders seeking the latest updates and insights on Polypid stock.
PolyPid Ltd. develops locally administered, controlled-release therapeutics based on its proprietary PLEX drug-delivery technology. The company’s lead product candidate, D-PLEX100, is designed for prevention of surgical site infections in abdominal colorectal surgery, and company updates commonly cover Phase 3 SHIELD II data, pharmacokinetics, FDA interactions, New Drug Application activity, and manufacturing-readiness topics.
PolyPid news also includes financial results, operational highlights, investor-conference participation, and broader pipeline references spanning surgical care, oncology, obesity, diabetes, and other metabolic-disease applications. Recurring disclosures focus on clinical and regulatory progress, product-candidate development, and the financing and business updates typical of a late-stage biopharmaceutical issuer.
PolyPid Ltd. (Nasdaq: PYPD) has received Breakthrough Therapy Designation from the FDA for D-PLEX100, aimed at preventing surgical site infections in elective colorectal surgery. This designation, attributed to promising Phase 2 clinical trial results, shows a 59% reduction in infections in the Intent to Treat population (p=0.0086) and 69% in the Per Protocol population (n=179; p=0.0024). D-PLEX100 also holds two Fast Track Designations and is in ongoing Phase 3 studies, demonstrating its potential in addressing serious surgical infection risks.
PolyPid Ltd. (Nasdaq: PYPD) announced significant progress in its Phase 3 SHIELD I trial for D-PLEX100, with over 50% of the 60 planned sites receiving IRB approval. The trial aims to prevent surgical site infections (SSIs) in abdominal surgery, enrolling 600-900 patients. Preparations for the second Phase 3 trial, SHIELD II, are underway. The company reported a net loss of $6.5 million for Q3 2020, up from $2.1 million in Q3 2019, and a total net loss of $31.4 million for the nine months ending September 30, 2020. Cash balance as of September 30, 2020, was $71.8 million, sufficient to fund operations into 2022.
PolyPid Ltd. (Nasdaq: PYPD) announced its participation in two investor conferences in November 2020. The company will present at the H.C. Wainwright 6th Annual Israel Conference on November 12 at 1:30 PM ET and at the Stifel 2020 Virtual Healthcare Conference on November 17 at 8:00 AM ET. Additionally, PolyPid will engage in one-on-one meetings during the AGP Virtual Healthcare Symposium on November 19. The company specializes in prolonging drug release using its proprietary PLEX technology, focusing on unmet medical needs, particularly with its lead product candidate, D-PLEX100, in Phase 3 trials.
PolyPid Ltd. (Nasdaq: PYPD) will report its third quarter 2020 financial results on November 11, 2020, before U.S. markets open. The company, focused on Phase 3 clinical development of its PLEX technology for prolonged-release therapeutics, will host a conference call at 8:30 AM ET to discuss results and business operations. Its lead candidate, D-PLEX100, targets surgical site infections and is in Phase 3 trials for various surgeries. More details can be found on the company's website.
PolyPid Ltd. (Nasdaq: PYPD) has initiated the SHIELD I trial, its first Phase 3 clinical study for D-PLEX100, aimed at preventing post-abdominal surgery incisional infections. The trial, which has enrolled its first patient, will assess the efficacy and safety of D-PLEX100 compared to standard care. Funded by a commitment to address surgical site infections, D-PLEX100 has previously shown significant promise in Phase 2 trials. Approximately 616 to 900 patients will be enrolled across 50 centers in the U.S., Europe, and Israel.
PolyPid Ltd. (Nasdaq: PYPD) has announced the pricing of its initial public offering (IPO) of 3,750,000 ordinary shares at $16.00 each, aiming to raise gross proceeds of $60 million. The shares are expected to start trading on the Nasdaq Global Market on June 26, 2020, with the offering set to close on June 30, 2020, pending customary conditions. The underwriters have a 30-day option to purchase an additional 562,500 shares at the IPO price. This offering follows the effectiveness of the registration statement by the SEC on June 25, 2020.